Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca 4Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

AstraZeneca 4Q08

Nexium sales were $1.3 billion in the quarter (+6%) but down 2% for the year to $5.2 billion. Losec/Prilosec sales were down 11% to $264 million in the quarter and down 14% to $1.1 billion for the year due to generic competition.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca

4Q Revenues: $8.2 billion (flat)

4Q Earnings: $1.3 billion (flat)

FY Revenues: $31.6 billion (+7%)

FY Earnings: $6.1 billion (+9%)

Comments: Nexium sales were $1.3 billion in the quarter (+6%) but down 2% for the year to $5.2 billion. Losec/Prilosec sales were down 11% to $264 million in the quarter and down 14% to $1.1 billion for the year due to generic competition. Crestor sales were $987 million in the quarter (+30%) and $3.6 billion for the year (+26%). Seloken /Toprol-XL sales were $207 million (+2%) in the quarter, but down 46% for the year to $807 million, impacted by generic competition. Symbicort sales were $514 million in the quarter (+29%) and $2.0 billion for the year (+22%). Pulmicort sales were down 10% in the quarter to $397 million due to the “at risk” launch of Teva’s generic in November. Pulmicort sales were flat for the year. Seroquel sales were $1.2 billion in the quarter (+10%) and $4.5 billion for the year (+9%). R&D expenses were $1.3 billion in the quarter (-5%) and flat for the year at $5.2 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters